India Is The World s Biggest Vaccine Maker. Yet Only 4% Of Indians Are Vaccinated
Update RequiredTo play audio, update browser or Flash plugin.
On June 25, people queued up to register for a COVID-19 vaccine at a site outside a Hindu temple in Hyderabad. Vaccinations are now being administered after a series of missteps led to a shortage of doses. If all goes well, India s public health agency hopes to be vaccinating up to 10 million people a day by late July.
Noah Seelam / AFP via Getty Images
MUMBAI – When Mumbai began lifting its coronavirus lockdown this month, Rekha Gala could finally reopen her late father s photocopy and stationary store, which she runs with her siblings in a jumble of low-slung businesses north of the city center.
India s Covaxin effectively neutralises Delta variant of Covid, says NIH
PTI
Washington |
Updated on
The adjuvant used Alhydroxiquim-II is the first authorised against infectious disease. India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said. The NIH said results of two blood serum studies from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively. The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and
Covaxin effectively neutralises Alpha, Delta variants, says US research institute
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India Covaxin efficacy against Alpha, Delta COVID-19 variants PTI
Updated Jun 30, 2021, 8:03 AM IST
India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.
NIV to study post-vax immune response
NIV to study post-vax immune response
ByVicky PathareVicky Pathare / Updated: Jun 30, 2021, 06:00 IST
Over 100 people vaccinated against COVID-19 will be included in the study conducted at Aundh District Hospital
The Pune-based
antibodies at Aundh District Hospital (ADH) to check the
immune response amongst people vaccinated against COVID-19. Over 100 people who have been immunised will be included in the study. The antibody level of the beneficiaries will be measured pre- and post-vaccination to get a clear picture on how strong antibodies are formed and how they last after vaccination.
Since the beginning of the
COVID immunisation programme, ADH has been using
Coronavirus: Kerala Changes COVID-19 Funeral Protocol; Allows Bodies To Be Taken Home ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.